Skip to content
OpenCapital
Get started

HTFL HTFL R&D credit carryforward

R&D credit carryforward at other companies

AZZ logo
AZZAZZ
$970K-80.8%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$6.99M-19.2%
HTF
Heartflow, Inc. Common StockHTFL
$7.63M+7.3%
Nuvation Bio logo
Nuvation BioNUVB
$23.38M+20.6%
Sylvamo logo
SylvamoSLVM
$0-100%
HRO
HarrowHROW
$4.79M+111%

Other financials

Income statement

See full
Revenue$52.6M+41.3%
Gross profit$42.2M+50.9%
Operating income-$29.5M-68.6%
Net income-$27.4M+15.4%
EPS (diluted)-$0.32+93.9%

Balance sheet

See full
Cash & equivalents$24.4M-78.7%
Total debt$26.3M—
Total equity$285.7M+132%
Total assets$344.0M—

Cash flow

See full
Operating cash flow-$30.1M-129%
CapEx$1.9M+71.6%
Free cash flow-$32.0M-124%

Valuation

See full
Market cap$2.97B—
Enterprise value$2.98B—
P/S15.5×—

Profitability

See full
Gross margin78.1%+2.4pp
Operating margin-39.7%-4.8pp
Net margin-58.4%-12.1pp
FCF margin-40.1%-2.4pp

Returns & leverage

See full
Return on equity37.1%—
Debt / equity0.1×—
Current ratio5.6×—

Where this comes from

Reported directly by HTFL in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.

The official record: HTFL’s 10-K, filed March 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about HTFL's r&d credit carryforward.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is HTFL's r&d credit carryforward?
HTFL (HTFL) reported r&d credit carryforward of $7.63M in Q4 2025.
What does r&d credit carryforward mean?
Represents the cumulative value of research and development tax credits that have not yet been utilized to offset tax liabilities. These assets can be carried forward to reduce future tax payments, providing a potential cash flow benefit. This metric highlights the company's historical investment in innovation and its future tax planning efficiency.